1 / 96

SB 207499 (Ariflo ® , cilomilast) GlaxoSmithKline New Drug Application 21-573

SB 207499 (Ariflo ® , cilomilast) GlaxoSmithKline New Drug Application 21-573. Pulmonary - Allergy Drugs Advisory Committee Meeting Holiday Inn Gaithersburg, Maryland 5 September, 2003. Pulmonary and Allergy Drug Products Advisory Committee Meeting September 5, 2003.

july
Download Presentation

SB 207499 (Ariflo ® , cilomilast) GlaxoSmithKline New Drug Application 21-573

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. SB 207499 (Ariflo®, cilomilast)GlaxoSmithKlineNew Drug Application 21-573 Pulmonary - Allergy Drugs Advisory Committee Meeting Holiday Inn Gaithersburg, Maryland 5 September, 2003 Pulmonary and Allergy Drug Products Advisory Committee Meeting September 5, 2003

  2. The Drug & Development Program • SB 207499 (phosphodiesterase IV inhibitor) • new molecular entity • first drug in its class • twice daily oral dosing • Indication: “…maintenance of lung function (FEV1) in patients with Chronic Obstructive Pulmonary Disease (COPD) who are poorly responsive to albuterol.” • Multi-national development program • Europe, Australia, Japan, New Zealand, North America, South Africa

  3. Presenters • Preclinical Pharmacology-Toxicology • Virgil Whitehurst, Ph.D. • Dose-Finding • Sandra Suarez, Ph.D • Statistics • James Gebert, Ph.D. • Efficacy & Safety • Raymond Anthracite, M.D.

  4. Preclinical Considerations Virgil Whitehurst, Ph.D. Pharmacologist

  5. Characterization of Toxicological Profile • Identify target organs of toxicity • Identify the no-observed-adverse-effect-level (NOAEL) in animals • Determine severity, reversibility and monitorability of the toxicity • Determine the margin of safety, a ratio based on exposure (e.g., AUC) comparison between animal (NOAEL in the sensitive species) and human

  6. Toxic Effects of Cilomilast in Animals • Arteritis (multi-organs), including the mesentery • Testicular Degeneration • Adrenal Cortex Hypertrophy • Myocardial Necrosis • GI Disturbances

  7. Arteritis • Arteritis appears to be a class effect of PDE-4 inhibitors (rolipram and others). Other PDE inhibitors, such as theophylline, also induce arteritis. • Arteritis is irreversible in animals. • Arteritis induced by cilomilast occurs in animals at an AUC that is only a fraction of the expected human AUC.

  8. Cilomilast Induced Arteritis

  9. Summary – Cilomilast (1) • Cilomilast induced arteritis and death in rats. • The severity of the toxicity in rats increases over a narrow range of exposure. • Human exposure at the proposed clinical dose is higher than the toxic dose in the rat.

  10. Summary – Cilomilast (2) • Therefore, the data provide no margin of safety for arteritis compared to the proposed clinical dose regimen • Arteritis is a significant safety concern

  11. NDA 21-573 Ariflo Immediate Release Tablets Study 032: Dose-Response CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW Sandra Suarez-Sharp, Ph.D.

  12. N Dose baseline Week 6 0 106 91 5 109 95 10 102 85 15 107 90 * * * * * * Study 032: Multiple Administration of Oral Cilomilast (5, 10 and 15mg Twice Daily) for 6 Weeks to Patients with COPD Mean (SEM) change from baseline in trough pre-bronchodilator FEV1 by week and treatment group * p<0.02

  13. Cilomilast Trough Concentration as a Function of Dose and Visit WEEK 1 WEEK 2 WEEK 4 WEEK 6 3000 Cilomilast trough concentration (ng/mL) 2000 1000 0 0 5 10 15 5 10 15 5 10 15 5 10 15 Dose (mg)

  14. Baseline FEV1 as a Function of Dose 4 Baseline FEV1 (L) 3 2 Baseline FEV1 (L) 1 0 0 5 10 15 Dose (mg)

  15. 0 mg 5 mg 10 mg 15 mg Change from Baseline in FEV1 after Baseline Adjustment 0.2 0.15 0.1 Change from baseline in FEV1 (L) 0.05 0 1 2 4 6 -0.05 Week

  16. 2.0 1.2 0.4 -0.4 -1.2 Change from Baseline in FEV1-Cilomilast Trough Concentration Relationship 0 1000 2000 3000 WEEK 4 WEEK 6 Change from baseline in FEV1 (L) WEEK 1 WEEK 2 2.0 1.2 0.4 -0.4 -1.2 0 1000 2000 3000 Cilomilast trough concentration (ng/mL)

  17. Adverse Experiences (GIT) Occurring in more than 5% of Patients in Any Treatment Group (% of Patients) Abd Pain Diarrhea Nausea Vomiting 12 10 8 Percentage AE 6 4 2 0 0 5 10 15 0 5 10 15 0 5 10 15 0 5 10 15 Dose (mg)

  18. NAUSEA VOMITING D: 0 0 5 5 10 10 15 15 0 5 10 15 3 5 6 3 5 6 3 5 6 3 5 6 3 6 46 456 3 6 46 456 3 6 46 456 3 6 46 456 Visit Visit Cilomilast Trough Concentration in Patients Experiencing GIT Side Effects vs. No AEs NO AEs ABDOMINAL PAIN 5 10 15 2000 1500 Cilomilast trough concentration (ng/mL) 1000 500 0 3 34 4567 3 34 4567 3 34 4567 3 34 4567 4 5 6 7 4 5 6 7 4 5 6 7 Visit Visit

  19. CONCLUSIONS • Dose-response relationship was not fully addressed by the sponsor. Data from Study 032 is not robust enough and 10 mg dose was not tested in Phase III clinical trials. • The lack of concentration-response relationship may be due to: • large degree of variability in the Cilomilast plasma trough concentrations (CV>60%) • Unbalanced data • A higher incidence of side effects (such as nausea, abdominal pain, diarrhea) was observed with increasing doses of Cilomilast.

  20. CONCLUSIONS, cont. • Plasma concentrations increased proportionally to dose, however no clear correlation between trough concentrations of Cilomilast and some adverse events (AEs) was observed, most likely due to: • the variability of the data • No correlation between Cilomilast trough concentrations and side effects.

  21. ACKNOWLEDGEMENTS • He Sun, Ph.D. • Emmanuel O. Fadiran, Ph.D. • Henry Malinowski, Ph.D.

  22. Ariflo®Glaxo Smith KlineNDA 21573 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland September 5, 2003 Statistical Reviewer: James Gebert Pulmonary and Allergy Drug Products Advisory Committee Meeting September 5, 2003

  23. Topics • Hochberg Procedure • Repeated Measures Analyses • Endpoint Analyses • Sample Size Discussion • Sponsor’s Delta

  24. Hochberg Procedure • Modified Bonferroni procedure • Both endpoints significant if both p-values <0.05. • One endpoint significant if p<0.025. • Statistical significance not clinical significance • 95 % confidence limits on treatment difference no longer appropriate • May be inappropriate in regulatory setting because of risk benefit considerations. Both may need to be significant. • What if different endpoints significant in two different studies? How do you write label?

  25. Repeated Measures Analyses • Compares treatments over 24 weeks of treatment • No imputation of missing visit data • Underweighs dropouts • Overweighs earlier visits • Needs more assumptions (must specify correlation structure of visits)

  26. Endpoint Analyses • Little or no weight to earlier visits • All patients including dropouts given equal weight • No imputation of missing visit data • Equivalent to last visit analysis after doing LOCF • Usually larger delta but larger variability

  27. Sample Size • Chosen to have 90% power • 3 of 4 studies used 2:1 weighting • Alpha level was chosen to be 0.025 for both endpoints • Delta=120 ml for FEV1 • Delta=4 for SGRQ Total Score • May give statistical significance not clinical significance • Large sample size can show significance even if true delta is smaller than assumed delta • Large sample size gives better estimate of true delta

  28. Why Significance with Smaller Delta? • 90 % Power • Choice of 0.025 Significance Level

  29. Raymond Anthracite, M.D. Medical Officer Ariflo Immediate Release Tablets NDA 21-573 Clinical Considerations Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland September 5, 2003

  30. Background • 4 Pre-Clinical Toxicities • Mesenteric Arteritis • the most serious animal toxicity • found in 2 species • Remaining 3 will not be addressed • Dose Selection – we agree that the dose selected was appropriate for development • Statistics – we agree with appropriateness of the analyses chosen

  31. Efficacy & Safety Outline • EFFICACY • 4 Pivotal Trials • Co-Primary Endpoints • Trough FEV1 • SGRQ • Secondary Endpoints • SAFETY • AEs, SAEs, AE Withdrawals & Deaths • Emphasis On: • Gastro-Intestinal AEs (GIAEs) • Adequacy Of Evaluation For Mesenteric Arteritis

  32. Phase II - III Clinical Trials • Asthma Studies – 4 (n=1069) • COPD Studies – 12 (n=5162+) • adequate & well-controlled (pivotal) – 4 (n=2883) • long-term, uncontrolled safety – 2 (n=1069+) • supportive – 6 (n=1210) • mechanism of action – 3 (n=280) • dose finding – 2 (n=648) • cardiology safety – 1 (n=282)

  33. Phase III Pivotal Efficacy Trials • multi-national, multi-center, randomized, double-blind, placebo-controlled, parallel-group • 4-week single-blind placebo run-in period • 24-week double-blind treatment period • COPD patients 40-80 years of age (COPD criteria of ATS & ERS) • current and/or former smoking history > 10 pack-years

  34. Phase III Pivotal Efficacy Trials (cont.) • pre-albuterol FEV1/FVC < 0.70 at screening • post-albuterol FEV1: • 30 - 70% of predicted normal, inclusive • “poorly responsive to albuterol” = “fixed airway obstruction” = post-albuterol FEV1: • < 15% increase over baseline, OR • < 200 mL increase over baseline

  35. Phase III Pivotal Efficacy Trials (cont.)Similarities & Differences • 4 had the same co-primary efficacy endpoints and statistical analysis (039, 042, 091, 156) • FEV1 & SGRQ difference between treatments in mean change from baseline, each at p < 0.025 • 3 had the same randomization strategy (2:1, SB 207499 to PBO) & all 5 secondary efficacy endpoints (039, 042, 091) • 1:1 randomization (156) • COPD Symptom Score moved from diary to visit and excluded “breathlessness” (156) • 6-Minute Walk demoted to tertiary endpoint (156)

  36. Phase III Pivotal Efficacy Trials (cont.)Similarities & Differences • Albuterol or salbutamol responsiveness: • 180 mcg by MDI with spacer (039, 156) • 400 (360) mcg by MDI with spacer (042, 091) • Pharmacokinetic sampling (039, 091, 156) • 2-week, double-blind run-out (091) • SB 207499 patients re-randomized (1:1) to placebo or SB 207499 • placebo patients continued taking placebo

  37. Demographics & Disposition Of Phase III Pivotal COPD Trials (039, 042, 091, 156)

  38. Study 039

  39. Study 042

  40. Study 091

  41. ISE – MEAN TROUGH FEV1 (L) AT WEEK 24 AND AFTER 2-WEEK RUN-OUT

  42. Study 156

  43. ISE – Trough FEV1, Mean Change From Baseline, Difference Between Treatments & Statistical Significance

  44. Study 039

  45. Study 042

  46. Study 091

  47. Study 156

More Related